Stockreport

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

Coherus BioSciences, Inc.  (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com
PDF – In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and in [Read more]